CER Daily Newsfeed

Real-World Evidence Reveals Disproportionate Burden of COVID-19 on Immunocompromized

(10/13, The Pharma Letter) reports “New data from real-world evidence studies from Anglo-Swedish pharma major AstraZeneca highlight that immunocompromised (IC) individuals continue to face significant and disproportionate burdens from COVID-19. The two extensive studies show substantially higher rates of severe COVID-19 outcomes compared to the general population.” Full

VBID Phase II Progress Report Shows Promise and Potential

(10/13, Adam Healy, McKnight's Home Care) reports “The Centers for Medicare & Medicaid Services released its midway evaluation of Phase II of the Medicare Advantage Value-Based Insurance Design (VBID) model. The results reveal significant growth in participation, notable shifts in insurer behavior, and improved quality of care for consumers.” Full

Study Examines Prognostic Risk Factors of Face-to-Face vs Internet-Based Therapy for Depression

(10/12, Chelsie Derman, HCP Live) reports “...Led by Mariia Merzhvynska, MSc, of the department of psychology at University of Zurich, the new systematic review and meta-regression compared face-to-face therapy and internet-based therapy and both therapy’s association with PRF.” Full

FDA Prioritizes Guidance on AI, Cybersecurity, Pulse Oximeters in Stacked Schedule for 2024

(10/13, Nick Paul Taylor, MedTech Dive) reports “...In 2022 and 2023, the FDA’s A-lists featured 10 and four draft documents, respectively. The plan for 2024 is more ambitious, with the administration aiming to draft 18 documents on topics such as artificial intelligence, cybersecurity, real-world evidence and pulse oximeters.” Full